Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report
Precision and Future Medicine · 31.03.2026 · 10 (1) · 51-56
DOI: 10.23838/pfm.2026.00009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Precision and Future Medicine, erschienen am 31.03.2026. Verfasst von Kyuho Kim und 8 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Olanzapine is a second-generation antipsychotic drug associated with the development of type 2 diabetes. However, the development and remission of diabetes with glutamic acid decarboxylase (GAD) antibody (Ab) positivity related to olanzapine treatment have not been reported. Here, we present the case of a 33-year-old man taking olanzapine who was diagnosed with diabetes with GAD Ab positivity complicated by diabetic ketoacidosis (DKA). After discontinuation of the drug and tight glycemic control, his diabetes remitted, and the GAD Ab became negative spontaneously after 18 months. The classification of diabetes is challenging because of overlapping autoimmune and metabolic features. Olanzapine may have contributed to pancreatic β-cell apoptosis, which could potentially trigger autoimmunity and the development of type 1 diabetes-like features (DKA as the initial presentation, a low C-peptide level, and GAD Ab positivity). The rapid amelioration of hyperglycemia and weight reduction may be responsible for the remission of diabetes after the discontinuation of olanzapine.
Zitieren
APA
Kim, K., Seo, S. H., Hong, Y. J., Myung, W., Kim, B., Ahn, C. H., Choi, S. H., Jang, H. C., & Oh, T. J. (2026). Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report. Precision and Future Medicine, 10(1), 51-56. https://doi.org/10.23838/pfm.2026.00009
Vancouver
Kim K, Seo SH, Hong YJ, Myung W, Kim B, Ahn CH, et al. Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report. Precision and Future Medicine. 2026;10(1):51-56. doi:10.23838/pfm.2026.00009
BibTeX
@article{Kim2026,
author = {Kim, Kyuho and Seo, Soo Hyun and Hong, Yun Ji and Myung, Woojae and Kim, Bomi and Ahn, Chang Ho and Choi, Sung Hee and Jang, Hak Chul and Oh, Tae Jung},
title = {Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report},
journal = {Precision and Future Medicine},
year = {2026},
volume = {10},
number = {1},
pages = {51--56},
doi = {10.23838/pfm.2026.00009}
}
EUVIMED